EVOLUS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
EVOLUS, INC. (EOLS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$15.05 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-25.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2021-03-25
- EVOLUS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-12-31 was -$14.56M.
- EVOLUS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-09-30 was -$149.00K.
- EVOLUS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2019-03-31 was -$14.50M.
- EVOLUS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2019 was -$15.05M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 1 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-12-31 | -$14.56M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$14.71M derived: sum of 2 quarters · filed 2021-03-25 | -$15.05M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | -$149.00K 10-Q · filed 2019-11-04 | -$497.00K 10-Q · filed 2019-11-04 | ||||
| 2019-03-31 | -$14.50M 10-Q · filed 2019-05-01 | |||||
| 2019-02-28 | -$14.40M 10-Q · filed 2020-10-29 | |||||
| 2018-12-31 | $34.50M 10-Q · filed 2019-11-04 | $10.50M 10-K · filed 2019-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |